

PAS introduction

The NHS London Procurement Partnership is continuing the Patient Access Scheme/s (PAS) project initiated in 2013, which has now been expanded to encompass all PAS, both NICE-approved and those in the CDF.

NICE-approved PAS are detailed here: <https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit/list-of-technologies-with-approved-patient-access-schemes>

To sign up for the NICE-maintained Operational PAS Update email list, send an e-mail to PASLUMail@nice.org.uk with 'Operational PAS update' in the subject line.

The initial data gathering exercises, for the manual or non-discount schemes, enabled us to identify which schemes were being taken up by each trust across London. We aim, with your help, to make this a routine exercise for all PAS so that we can continually assess the cost avoidance derived and thus the benefit of the schemes for London NHS trusts.

The information received from previous data collection exercises indicates that there is a very high level of uptake, with a total cost avoidance for both discount and manual schemes of approximately £69 million in the 2015/2016 financial year. It shows that whereas the cost avoidance from simple discount PAS can be quantified accurately from usage data, assessing the other schemes requires more detailed information, which is only available from each trust.

Your help would be greatly appreciated to facilitate the collection of this data.

All information provided will remain confidential between the LPP and the trust providing the information. Our aim is not to criticise trusts that appear not to have taken up schemes for one reason or another but to assess the extent of uptake, understand the reasons for non-uptake, and provide support to maximise appropriate uptake.

Note that this online survey has been separated into cancer and non-cancer PAS.
Please provide data for the 2016/2017 financial year (04/2016 to 03/2017).

We would be grateful if you could provide the information requested in this survey by 31st October 2017.

If you have any further questions regarding the project please do not hesitate to contact Pauline McCalla pauline.mccalla@nhs.net

PLEASE NOTE THAT THIS ONLINE SURVEY MUST BE COMPLETED IN ONE SITTING; IT CANNOT BE SAVED PART WAY THROUGH AND STARTED AGAIN LATER.

FOR THE PURPOSES OF GATHERING THE DATA, WE RECOMMEND PRINTING OUT THE AUDIT TOOL FROM: [http://www.lpp.nhs.uk/categories/medicines-optimisation-pharmacy-procurement/secondary-care/patient-access-scheme\(s\)-project/](http://www.lpp.nhs.uk/categories/medicines-optimisation-pharmacy-procurement/secondary-care/patient-access-scheme(s)-project/), AND ENTERING THE DATA INTO THIS ONLINE SURVEY ONCE DATA COLLECTION HAS BEEN COMPLETED.

Thank you for your cooperation.

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

Trust name

* 1. Please pick your trust from the drop down list

- Barts Health NHS Trust
- Camden and Islington NHS Foundation Trust
- Central and North West London NHS Foundation Trust
- Chelsea and Westminster Hospital NHS Foundation Trust
- Croydon Health Services NHS Trust
- East London NHS Foundation Trust
- Epsom and St Helier University Hospitals NHS Trust
- Great Ormond Street Hospital For Children NHS Trust
- Guy's and St Thomas' NHS Foundation Trust
- Homerton University Hospital NHS Foundation Trust
- Imperial College Healthcare NHS Trust
- King's College Hospital NHS Foundation Trust
- Kingston Hospital NHS Trust
- Lewisham and Greenwich NHS Trust
- Moorfields Eye Hospital NHS Foundation Trust
- North East London NHS Foundation Trust
- North Middlesex University Hospital NHS Trust
- London North West Healthcare NHS Trust
- Oxleas NHS Foundation Trust
- Royal Brompton and Harefield NHS Foundation Trust
- Royal Free London NHS Foundation Trust
- Royal National Orthopaedic Hospital NHS Trust
- South London and Maudsley NHS Foundation Trust
- South West London and St George's Mental Health NHS Trust
- St George's Healthcare NHS Trust
- Tavistock and Portman NHS Foundation Trust
- The Hillingdon Hospitals NHS Foundation Trust
- The Royal Marsden NHS Foundation Trust
- The Whittington Hospital NHS Trust
- University College London Hospitals NHS Foundation Trust
- West London Mental Health NHS Trust
- Other (please specify)

Email address

* 2. Please provide your email address

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

PAS name: Bortezomib
PAS indication: Multiple Myeloma

3. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with Multiple Myeloma.

PAS implemented?	Estimated number of patients started on bortezomib as 2nd line treatment?	Of these, how many patients was reimbursement claimed for?
------------------	---	--

Bortezomib for multiple myeloma. Patients are eligible for the scheme if they fail to achieve at least a 50% reduction, after 4 cycles, in the most relevant marker e.g. serum paraproteins or serum light chains. [Click here to go to NICE TA129](#)

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

PAS name: Gefitinib
PAS indication: Non small cell lung cancer

4. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with Lung cancer.

PAS implemented?	Estimated number of patients for whom the £12,200 charge has been paid?	Estimated number of packs of free stock purchased?
Gefitinib for non small cell lung cancer. A single charge of £12,200 is applied when supplies for cycle 3 are purchased. Supplies are free thereafter. Click here to go to NICE TA192		
<input type="text"/>	<input type="text"/>	<input type="text"/>

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

PAS name: Lenalidomide
PAS indication: Multiple Myeloma or del 5q Myelodysplastic syndrome

5. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with that disease.

PAS implemented?	Estimated number of patients on lenalidomide treatment?	How many PAID packs of lenalidomide were received?	How many FREE packs of lenalidomide were received?
Lenalidomide for multiple myeloma / myelodysplastic syndrome. Patients are eligible for free stock if they remain on treatment for > 26 cycles. Click here to go to NICE TA171 / TA322			
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

PAS name: Sunitinib
PAS indication: Renal cell cancer

6. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with Renal Cell cancer.

PAS implemented?	Estimated number of patients started on sunitinib/ or number of FREE packs received?
Sunitinib for renal cell cancer / gastrointestinal stromal tumour. Patients initiated on treatment receive the first cycle free of charge. Click here to go to NICE TA169 / TA179.	
<input type="text"/>	<input type="text"/>

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

PAS name: Trabectedin
PAS indication: Advanced soft tissue **sarcoma**

7. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with Sarcoma.

PAS implemented?	Estimated number of patients started on trabectedin?	How many patients continued treatment for more than 5 cycles?	How many PAID cycles were received?	How many FREE cycles were received?
Trabectedin for advanced soft tissue sarcoma. Patients continuing treatment beyond cycle 5 receive stock free of charge. Click here to go to NICE TA185				
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

Non-cancer PAS drugs

Note that non-PAS indications should be excluded from data collection:

- Ankylosing spondylitis, axial ankylosing spondylitis & psoriatic arthritis for certolizumab pegol.
- Ulcerative colitis for golimumab.

8. Please enter N/A in the "PAS implemented?" column if your organisation does not treat patients with the condition covered by the PAS.

PAS implemented?	Estimated number of patients treated?	Number of free of charge doses provided?
Certolizumab pegol for rheumatoid arthritis. Under the scheme, the first 12 weeks of therapy (10 pre-loaded syringes of 200 mg each) are provided free of charge. Click here to go to NICE TA186		
<input type="text"/>	<input type="text"/>	<input type="text"/>
Golimumab for psoriatic arthritis / rheumatoid arthritis / ankylosing spondylitis. Under the scheme, 100 mg doses are provided at the same cost as the 50 mg dose. Click here to go to NICE TA220 / TA 225 / TA233		
<input type="text"/>	<input type="text"/>	<input type="text"/>
Ustekinumab for psoriasis. <u>Patients >100kg:</u> are provided a free 45mg vial to give each 90mg (2 x 45mg vials) dose. Click here to go to NICE TA180		
<input type="text"/>	<input type="text"/>	<input type="text"/>

Please provide any further information here

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

General information

9. Do you have any further comments about PAS or LPP's PAS work in general?

Please also tell us if you are aware of any manually-managed (i.e. non-straightforward discount) schemes that are not covered by this survey.

Please state the drug name, the NICE TA number and the number of eligible patients.

NHS London Procurement Partnership Patient Access Scheme Audit 2016/17
(RETROSPECTIVE)

Final page

Thank you for your co-operation in completing this survey.
Your time and effort is greatly appreciated.

Kind regards,

Pauline

